Re-challenging taxanes in recurrent breast cancer in patients treated with (Neo-)adjuvant taxane-based therapy

Breast Care

Volumn 6, Issue 4, 2011, Pages 279-283

  Guo, Xinrong ^a   Loibl, Sibylle ^a   Untch, Michael ^b   Möbus, Volker ^c   Schwedler, Kathrin ^c   Fasching, Peter A ^d   Barinoff, Jana ^e   Holms, Frank ^f   Thomssen, Christoph ^g   Zahm, Dirk M ^h   Kreienberg, Rolf ⁱ   Hauschild, Maik ^j   Eidtmann, Holger ^k   Tauchert, Sascha ^l   Mehta, Keyur ^a   Von Minckwitz, Gunter ^a  

^a C/o GBG Forschungs GmbH ^*  (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e DR HORST SCHMIDT KLINIKEN   (Germany)

^f Barbaraklinik   (Germany)

^g MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^h ETL Advision   (Germany)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j Frauenklinik Rheinfelden   (Germany)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l Caritasklinik St Theresia   (Germany)

more..

Author keywords

Adjuvant; Docetaxel; Paclitaxel; Recurrent breast cancer

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; HORMONE RECEPTOR; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; DISEASE FREE INTERVAL; DRUG RECHALLENGE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; VISCERAL METASTASIS;

EID: 80052908255     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000330946     Document Type: Article

References (27)

1. Conlin AK, Seidman AD: Taxanes in breast cancer: an update. Curr Oncol Rep 2007;9:22-30. (Pubitemid 46075630)
2. Eniu A, Palmieri FM, Perez EA: Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 2005;10:665-685. (Pubitemid 41567278)
3. Perez EA: Paclitaxel in breast cancer. Oncologist 1998;3:373-389. (Pubitemid 29009301)
4. Jackisch C, Untch M, Chatsiproios D, et al.: Breast cancer: analysis of treatment quality in Germany 2004: retrospective survey by Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). Zentralbl Gynakol 2006;128:352-361. (Pubitemid 46102233)
5. Diagnosis and treatment of patients with primary and metastatic breast cancer. Recommendations of the Breast Commission of the Working Group Gynaecologic Oncology. www.ago-online.de/index. php?lang = en and site = mamma-guide-topical and topic = mamma-guide.
6. von Minckwitz G, Raab G, Caputo A, et al.: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPAR-DUO study of the German Breast Group. J Clin Oncol 2005;23:2676-2685. (Pubitemid 46179457)
7. von Minckwitz G, Blohmer JU, Raab G, et al.: In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005;16:56-63. (Pubitemid 40124479)
8. von Minckwitz G, Kummel S, Vogel P, et al.: Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:552-562.
9. von Minckwitz G, Kummel S, Vogel P, et al.: Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:552-562.
10. von Minckwitz G, Rezai M, Loibl S, et al.: Capecitabine in addition to anthracycline/taxanebased neoadjuvant treatment in patients with primary breast cancer: the phase III GeparQuattro study. J Clin Oncol 2010;28:2015-2023.
11. Untch M, Rezai M, Loibl S, et al.: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010;28:2024-2031.
12. Untch M, Fasching PA, Konecny GE, et al.: PRE-PARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer - results at the time of surgery. Ann Oncol, in press.
13. Untch M, von Minckwitz G, Konecny GE, et al.: PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer - outcome on prognosis. Ann Oncol, in press.
14. Untch M, Fasching PA, Konecny GE, et al.: Pathological complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in HER2-overexpressing breast cancer - Results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol, in press.
15. Loibl S, Mueller V, von Minckwitz G, et al.: Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer, in press.
16. ®) zur Therapie des Mammakarzinoms. Höchste Wirksamkeit bei moderaten Nebenwirkungen. Med Klin 1997;92(suppl IV):4-9. (Pubitemid 127820197)
17. Chan S, Friedrichs K, Noel D, et al.: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-2354. (Pubitemid 29368232)
18. Nabholtz JM, Falkson C, Campos D, et al.: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-975. (Pubitemid 46594123)
19. Marty M, Cognetti F, Maraninchi D, et al.: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptorpositive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274. (Pubitemid 46207001)
20. Nabholtz JM, Mackey JR, Smylie M, et al.: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001;19:314-321. (Pubitemid 32114144)
21. Nabholtz JM, Gelmon K, Bontenbal M, et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-1867. (Pubitemid 26185461)
22. Seidman AD, Berry D, Cirrincione C, et al.: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-1649.
23. Gianni L, Munzone E, Capri G, et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-2699.
24. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
25. Rivera E, Gomez H: Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 2010;12(suppl 2):S2.
26. Huober J, von Minckwitz G, Denkert C, et al.: Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010;124:133-140.
27. Liedtke C, Mazouni C, Hess KR, et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.